NEW YORK — NuProbe said on Thursday that it has granted a worldwide license for its proprietary blocker displacement amplification (BDA) technology to Oxford Nanopore Technologies.
Financial terms of the deal were not disclosed.
According to NuProbe, the BDA technology selectively amplifies low-abundance sequence variants in a background of wildtype DNA and can be combined with nanopore sequencing to enable greater detection sensitivities and quantification of somatic mutations at less than 5 percent allele frequency.